What FOXO4-DRI is

FOXO4-DRI is a synthetic peptide designed to interfere with the interaction between two proteins: the transcription factor FOXO4 and the tumour suppressor p53. The name describes the construction. It is a D-retro-inverso (DRI) peptide — the amino-acid sequence of the FOXO4 forkhead domain, reversed and rebuilt from D-amino acids — fused to a cell-penetrating sequence derived from HIV-TAT to help it cross cell membranes. The mirror-image chemistry makes the peptide markedly more resistant to breakdown than its L-amino-acid equivalent.

The compound was introduced in the study by Baar and colleagues published in Cell in 2017 [1]. Later structural work (Bourgeois et al., 2025) resolved how it binds: directly to the transactivation domain 2 (TAD2) of p53, competing with FOXO4 for the same site [2].

The mechanism: forcing senescent cells to self-destruct

Cellular senescence is a state in which a cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete inflammatory factors — the senescence-associated secretory phenotype — that damage the surrounding tissue. Clearing them is one of the lines of research pursued in ageing biology.

In senescent cells, FOXO4 and p53 sit together in the nucleus, and that interaction helps keep the cell alive. FOXO4-DRI disrupts it. p53 is released and moves to the mitochondria, where it triggers apoptosis — programmed cell death — selectively in senescent cells, with little effect on non-senescent cells in the same cultures [1][2]. The 2025 structural study measured the peptide's affinity for the p53 TAD2 region and showed that phosphorylation of p53 at two sites, Ser46 and Thr55, strengthens the binding [2].

What the evidence shows — and where it stops

The FOXO4-DRI record is entirely preclinical. No human clinical trial of the compound has been reported in the indexed literature, and the authors of the most recent animal study state plainly that their work remains some way from clinical application [4]. The published studies break down as follows.

  • 2017 — Cell (mouse models). Baar et al. reported that FOXO4-DRI selectively killed senescent cells and restored tissue homeostasis in mouse models of chemotherapy-induced damage and natural ageing [1]. This is the founding report and the source of almost every subsequent claim.
  • 2020 — Aging (aged mice). Zhang et al. used the peptide to target senescent Leydig cells in aged mice, reporting effects on age-related testosterone secretion [5].
  • 2021 — Frontiers in Bioengineering and Biotechnology (human cells in vitro). Huang et al. applied FOXO4-DRI to human chondrocytes expanded in culture and found it removed more than half of the senescent cells without harming the non-senescent ones — but the retained cells did not regain their cartilage-forming potential [3]. A clean clearance result that did not translate into the functional outcome the authors had hoped for.
  • 2026 — Frontiers in Bioengineering and Biotechnology (mice and cells). Hu et al. reported that FOXO4-DRI reduced endothelial-cell senescence and improved aortic function in naturally aged and progeroid mice, acting through the p53/BCL-2/caspase-3 pathway [4]. The same paper states the work is preclinical and that safety and efficacy remain to be verified.

By the standard Peptide Data applies to every compound, this is not enough for more than a Limited grade. There is a substantial, mechanistically coherent preclinical signal; there is no controlled human data of any kind.

The regulatory position in the UK

FOXO4-DRI is not a licensed medicine anywhere, including in the UK, and it does not appear on the MHRA's register of licensed products. It is also not a controlled drug under the Misuse of Drugs Act 1971.

That distinction matters. Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a product presented for a medicinal purpose — treating, preventing or diagnosing disease, or otherwise restoring, correcting or modifying physiological function — is a medicine, and supplying an unlicensed medicine in the UK is unlawful outside narrow exemptions. Whether a particular peptide is being presented as a medicine is a case-by-case judgement. The MHRA applies a borderline test that looks at the product's presentation, its function and the claims made for it [7][8][9].

Suppliers typically sell FOXO4-DRI labelled "for research use only". That label describes an intended use; it is not a legal shield. Where a product is sold in circumstances that indicate human use — dosing guidance, human-use claims, or a presentation that invites consumption — the MHRA can treat it as an unlicensed medicine whatever the label says [7].

Commercially, the compound's founding academic work led to the formation of a preclinical company (Cleara Biotech), which remains focused on the broader FOXO4–p53 interaction rather than on FOXO4-DRI as a product; other groups have since taken it up as a laboratory tool [6]. No FOXO4-DRI product has progressed to clinical development.

What would count as progress

FOXO4-DRI is a well-characterised laboratory tool with an unusual and specific mechanism. What it is not is a compound with human data. The developments that would change its evidentiary standing are the ones absent today: a registered Phase 1 study establishing human safety and pharmacokinetics, published human concentration and clearance data, and any controlled trial with a prespecified endpoint. Until those exist, the FOXO4-DRI record is a cell-culture and rodent record, and it should be read as one.

This article describes the research literature only. FOXO4-DRI is not a licensed medicine, and nothing here is guidance on its use in humans.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.